#direct-acting antivirals

Only 20% of people covered by Medicaid received treatment within six months of their HCV diagnosis.

Modern antivirals can cure 95% of people with HCV, lowering the risk of cirrhosis, liver cancer and liver failure.

Adding ribavirin led to more side effects but did not improve the likelihood of a cure.

The CDC estimates that 21% of people living with HIV also have hepatitis C virus.

Drug-related mortality, including overdose, was the leading cause of death.

Researchers are working on a cure for hepatitis B and a vaccine and long-acting antivirals for hepatitis C.

A “jarringly low” proportion of people with HCV have been tested, treated and cured.

However, those with Medicaid coverage were less likely to start treatment compared to those with other types of insurance.

Recent drug use along with unstable housing increased the risk of acquiring HCV again.

The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

Cutting the duration of treatment also cut the likelihood of a cure.

Two thirds of people who currently use drugs completed treatment, and most of those were cured.

Mavyret was associated with the most improvement in post-traumatic stress disorder symptoms.

Left untreated, hepatitis C can lead to cirrhosis, liver cancer and the need for a liver transplant.